Table 1.

Investigator-assessed objective response to axitinib: overall and by histologic subtype

	Complete response	Partial response	Stable diseasea	Progressive disease	Indeterminate	Missing
	n (%)	n (%)	n (%)	n (%)	n (%)	n (%)
All patients (N = 60)	0	23 (38)b	18 (30)	5 (8)	9 (15)	5 (8)
Histologic subtype
Papillary (n = 30)	0	10 (33)	10 (33)	3 (10)	4 (13)	3 (10)
Follicular (n = 15)c	0	9 (60)	4 (27)	1 (7)	1 (7)	0
Medullary (n = 11)	0	2 (18)	3 (27)	0	4 (36)	2 (18)
Anaplastic (n = 2)	0	1 (50)	0	1 (50)	0	0
Other (n = 2)	0	1 (50)d	1 (50)e	0	0	0

^aLasting ≥16 weeks. Of the 18 patients with stable disease ≥16 weeks, 17 had stable disease ≥30 weeks

^b95 % confidence interval 26–52

^c11 patients had the Hürthle cell variant

^dInsular

^eNeuroendocrine